相关实验视频
Updated: Jun 13, 2026

10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.7K
在体外释放动力学阿托瓦斯塔丁载的酸颗粒用于增强的牙周治疗
Imke Hlawa1, Thomas Reske2, Oleksandra Chabanovska1
1Department of Operative Dentistry and Periodontology, Rostock University Medical Center, 18057 Rostock, Germany.
Polymers
|February 13, 2025
概括
使用超声波创建的新型阿尔金酸微粒为阿托瓦斯塔丁治疗牙周炎提供了稳定,可控的输送系统,可能会改善目前的方法.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 牙周治疗药物 牙周治疗药物
背景情况:
- 牙周炎是一种慢性炎症性疾病,导致牙脱落.
- 类药物显示出作为治疗牙周炎的抗炎药物的前景.
- 有效的局部药物输送系统是需要的牙周类他类药物治疗.
研究的目的:
- 开发和评估超声波辅助的酸微粒,用于局部阿托瓦斯塔丁的输送.
- 与传统水凝相比,评估这些微粒的稳定性和药物释放特性.
主要方法:
- 使用超声波辅助技术将阿托瓦斯塔丁封装成酸微粒 (10-400μm).
- 微粒在37°C的人工唾液中化,以模拟生理条件.
- 使用高性能液体染色学量化药物释放;甲基纤维素水凝作为对照.
主要成果:
- 酸微粒显示,与甲基纤维素相比,平均溶解时间增加了10倍以上,表明稳定性得到了增强.
- 增加阿托瓦斯塔丁度将50%的药物释放时间 (t50%) 从1小时延长到11小时.
- 酸与二维нил硫的共价交叉链接进一步延迟了最初的药物释放时间3小时 (p < 0.05).
结论:
- 超声波辅助制造对于生产用于药物输送的稳定酸盐微粒是有效的.
- 这些酸盐微粒为牙周治疗中局部化他类药物提供了一个有希望的,生物相容的载体.
- 开发的系统解决了在临床牙科中改善药物载体的需求.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

